We rely on peer-reviewed scientific research to determine what’s truly effective. Our goal is to provide clear, unbiased information to help you make better health decisions.
We use AI tools to help summarize studies, and every piece of content is reviewed and approved by qualified experts, ensuring it’s accurate and trustworthy.
Beta Glucan is fully independent — we don’t sell products, run ads, or accept sponsorships. Our only focus is delivering reliable, science-backed insights.
Key study details
Objective
To review current advances in respiratory mucosal vaccines, including the mechanisms governing mucosal immunity, technological innovations in vaccine platforms and adjuvants, and the clinical progress and challenges associated with developing vaccines that induce robust protection at the respiratory mucosa.
Methods
This narrative review synthesizes mechanistic, preclinical, and clinical evidence on respiratory mucosal immunity. It integrates data on epithelial and innate immune barriers, antigen‑uptake pathways, adaptive mucosal memory, biomarkers of protection, and vaccine delivery technologies. The authors also evaluate mucosal adjuvants—including toxoid derivatives, chitosan, β‑glucan, and polymer‑based systems—and summarize safety considerations and clinical trial findings where available.
Results
The review highlights that mucosal vaccines can induce secretory IgA (SIgA), tissue‑resident memory T cells (TRMs), and localized germinal center responses that are not efficiently generated by intramuscular vaccines. Mechanistic pathways include antigen sampling by M cells and dendritic cells, cytokine‑driven TRM differentiation (e.g., IL‑13, IL‑17), and mucosal homing via chemokine gradients. Several adjuvants—such as LThaK, CTA1‑DD, chitosan, and β‑glucan—enhance antigen uptake, APC activation, and mucosal antibody production. Safety concerns remain for certain intranasal adjuvants (e.g., LT derivatives), though newer formulations show improved tolerability. No dosing regimens or adverse‑event profiles were reported for β‑glucan beyond noting its preclinical status and lack of observed toxicity in cited studies.
Our take
Interpretation
Respiratory mucosal vaccines offer immunological advantages by targeting the site of pathogen entry and inducing SIgA‑mediated immune exclusion, TRM‑mediated rapid recall responses, and broader mucosal immune activation. Adjuvants such as β‑glucan may enhance mucosal immunity by promoting cytokine production and T‑cell activation, though evidence remains preclinical. The review underscores that mucosal vaccine efficacy depends on overcoming physical barriers, avoiding mucosal tolerance, and ensuring safe delivery to epithelial and immune cells.
Limitations
The review is limited by the early developmental stage of many mucosal vaccine candidates and adjuvants. Clinical data remain sparse, especially regarding long‑term safety, durability of SIgA responses, and performance in antigen‑naïve versus antigen‑experienced populations. The heterogeneity of mucosal immune responses across individuals complicates biomarker identification. β‑glucan‑based adjuvants are discussed only at a conceptual and preclinical level, without detailed mechanistic or dosing data.
Implications
Respiratory mucosal vaccines may play a critical role in preventing infection and transmission of respiratory pathogens by strengthening frontline immunity. Continued innovation in adjuvant design—including polysaccharide‑based systems such as β‑glucan—and delivery platforms is essential to improve antigen stability, uptake, and safety. Validating mucosal correlates of protection (e.g., SIgA, TRMs) will be key for advancing candidates into clinical use and guiding next‑generation vaccine development.
This summary is based on peer-reviewed scientific research. We use AI tools to help condense complex studies, but all content is reviewed and approved by qualified experts before publication.
Citation
Copied!